{"ticker": {"uuid": "084b9c85-ba73-4af3-a95e-85f598358c02", "symbol": "INBX", "name": "Inhibrx Biosciences, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQOWpidFh1WDNOcnJPWXlhX1Q0LTUyWVowa2hELXhBc0c4NEFMVFpwVGZ4c0dHaUxBUTB6bi1YN0p2dXhVcjBJaUJMOC0zTzh5X3EtRngwX0pWRXpXNHB1M2FLUEdLaE5WekxYTEFsVzc1ZmtHOURzZ3Fnenk1YTdieE9nSk9sX0d6WGJORmtnMnFsVVpoT1VscXB5LWkyNVVQRGUtMkRfbWhKQXd2?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-17T10:43:05+00:00", "published_display": "17 Jul 2026 10:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million", "summary": "Inhibrx Biosciences has expanded its loan facility with Oxford Finance to $500 million through a second amendment to their agreement. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately as a Term C Loan and an additional $225 million ", "url": "https://www.bitget.com/amp/news/detail/12560605510756", "source_name": "Bitget", "published_at": "2026-07-17T08:39:58", "published_display": "17 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants", "summary": "Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collat", "url": "https://www.tradingview.com/news/tradingview:aa55e8e1012b4:0-inhibrx-biosciences-expands-oxford-credit-facility-to-500-million-draws-100-million-issues-warrants/", "source_name": "TradingView", "published_at": "2026-07-16T20:11:03", "published_display": "16 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit", "summary": "Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an 8", "url": "https://www.stocktitan.net/sec-filings/INBX/8-k-inhibrx-biosciences-inc-reports-material-event-d6a556c7ff36.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:11:03", "published_display": "16 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million", "summary": "Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its dr", "url": "https://www.moomoo.com/th/news/post/73079525/press-release-inhibrx-announces-amended-loan-agreement-with-oxford-finance", "source_name": "Moomoo", "published_at": "2026-07-16T19:10:59", "published_display": "16 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/inhibrx-announces-amended-loan-agreement-130000546.html", "source_name": "PR Newswire", "published_at": "2026-07-16T13:00:00+00:00", "published_display": "16 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Gets $100 Million Now; Lenders May Fund $225 Million More", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOYjQ3Y2VWakZIbDVyU25jVzBnc2wyX3l0N2t6cmdZNkQyOE9Qby1nQ3oxZUxnSXE2VTFDNWQwRGVIWmxXYWFTMF9IUHBDaVpNdEJlVEgtS0Q3dzNRU2hnSzhfZVVTT3RBaHN4NHRZUTRab1d3eklIeWtCMDB2bnctWHlwMEZqOXlGZ2dldjEtM2F0WXVQWUM4eGFNR3piUTlsOEplQ0V3V3VLUGJ0elB5OXYtTklIUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T13:00:00+00:00", "published_display": "16 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price-Driven Insight from (INBX) for Rule-Based Strategy", "summary": "Inhibrx Biosciences Inc (NASDAQ: INBX) is showing strong sentiment across all horizons, supporting an overweight bias. AI models have generated three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles. The analysi", "url": "https://news.stocktradersdaily.com/news_release/1/Price-Driven_Insight_from_INBX_for_Rule-Based_Strategy_071226045802_1783889882.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T16:58:00", "published_display": "12 Jul 2026 16:58", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Inhibrx Biosciences' (INBX) Shift Into Russell Growth Indexes Reframe Its Core Investment Story?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPSzY4SmFpbDViUk9tTXQ2NS15X1pYZUhqNVZlY2tWak5udkdGcGxRVW5XYjdSVWg5dDM1UlJkVUlXNXd3ZDdiaXBILUlvQWR3Wnl2UmNScHVVczZfbUJ4TzRWOGJHYUl6VjYwZEFEQzJxQS1NRFN1SExjcTEwNDR5Y1k4MGZXeFlIdFpCcGc0YlEwQV9EUC1hWnNR?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights", "summary": "This report provides a stock analysis for Inhibrx Biosciences (INBX), a clinical-stage biopharmaceutical company. It details the company's general information, current stock performance, and a methodology for grading the stock based on various financial metrics. The analysis high", "url": "https://es.benzinga.com/quote/INBX/report", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-07T06:11:48", "published_display": "07 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors", "summary": "Inhibrx Biosciences (INBX) was reclassified from Russell value/defensive indices to growth/small-cap indices in late June 2026. This shift primarily affects the type of investors holding the stock and doesn't change the underlying business catalysts, which include regulatory prog", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inbx/inhibrx-biosciences/news/how-russell-index-reclassification-toward-growth-benchmarks", "source_name": "Simply Wall Street", "published_at": "2026-07-03T02:40:11", "published_display": "03 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(INBX) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) price dynamics, identifying a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 97.2:1 risk-reward setup, targeting a substantial gain with minimal risk. The analysis provides t", "url": "https://news.stocktradersdaily.com/news_release/9/INBX_Price_Dynamics_and_Execution-Aware_Positioning_070126035001_1782935401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T15:40:44", "published_display": "01 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index", "summary": "Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been removed from the Russell 2000 Defensive Index. This change is part of broader index adjustments, as the company was also added to other Russell indices like the Russell 2500 Growth and Russell 2000 Growth Benchmarks around the s", "url": "https://www.marketscreener.com/news/inhibrx-biosciences-inc-nasdaqgs-inbx-dropped-from-russell-2000-defensive-index-ce7f5fdfdc8af427", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:12:39", "published_display": "29 Jun 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?", "summary": "Inhibrx Biosciences (INBX) received FDA acceptance for its Biologics License Application for ozekibart, following positive Phase III data. Despite significant past share price momentum and an analyst target considerably higher than the current trading price, the company's financi", "url": "https://www.sahmcapital.com/news/content/inhibrx-biosciences-inbx-wins-fda-filing-acceptance-is-more-upside-already-priced-in-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-29T13:12:39", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark", "summary": "Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been added to the Russell 3000E Growth Benchmark. This pharmaceutical company, which specializes in developing novel biologic therapeutic candidates, is actively advancing its clinical pipeline, including therapies like ozekibart (IN", "url": "https://www.marketscreener.com/news/inhibrx-biosciences-inc-nasdaqgs-inbx-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:41:49", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index", "summary": "Inhibrx Biosciences, Inc. (NasdaqGS:INBX) has been removed from the Russell 2000 Value-Defensive Index. This change is part of broader Russell index reconfigurations, which also saw the company dropped from other defensive/value benchmarks and added to growth benchmarks like the ", "url": "https://www.marketscreener.com/news/inhibrx-biosciences-inc-nasdaqgs-inbx-dropped-from-russell-2000-value-defensive-index-ce7f5fdfde80f325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:09:48", "published_display": "29 Jun 2026 03:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Inhibrx Biosciences, Inc. \u2013 NASDAQ:INBX", "summary": "This article provides a financial snippet for Inhibrx Biosciences, Inc. (NASDAQ: INBX), focusing on its enterprise value to revenue forward metric. It details that the market is currently closed with no trades recorded for the company. The content appears to be a stub or a brief ", "url": "https://www.tradingview.com/symbols/NASDAQ-INBX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:12", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Inhibrx Biosciences, Inc. \u2013 NASDAQ:INBX", "summary": "This article provides financial data, specifically the \"Price to sales forward\" for Inhibrx Biosciences, Inc. (NASDAQ: INBX). It notes that the market is closed with no trades recorded at the time of publication and lists the company on the Nasdaq Stock Market. The content is pri", "url": "https://www.tradingview.com/symbols/NASDAQ-INBX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:34", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Jun 2026", "summary": "Inhibrx Biosciences (INBX) reported a short interest of 3.30 million shares as of June 15, 2026, representing 27.52% of its public float, an increase of 3.79% from the previous report. The short interest ratio is 10.3 days to cover, indicating significant pessimism towards the st", "url": "https://www.marketbeat.com/stocks/NASDAQ/INBX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T00:10:12", "published_display": "26 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INBX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Inhibrx Biosciences, Inc. (INBX) stock, including analyst price targets, past performance, and basic financial information. It notes that analysts have a maximum estimate of $325.00 and a minimum estimate of $230.00 for INBX's future price. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-INBX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:10:07", "published_display": "25 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More", "summary": "This article highlights six biotech stocks (Inhibrx Biosciences, Palvella Therapeutics, MBX Biosciences, Protagonist Therapeutics, Absci Corp., and Belite Bio Inc) that have shown significant gains for long-term investors. It details the clinical developments, positive trial resu", "url": "https://www.rttnews.com/amp/3662423/6-biotech-stocks-that-delivered-stunning-gains-inbx-700-pvla-500-mbx-300-absi-200-more.aspx", "source_name": "RTTNews", "published_at": "2026-06-24T13:39:50", "published_display": "24 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart", "summary": "Inhibrx Biosciences' investment narrative is shifting due to the FDA's acceptance of its Biologics License Application (BLA) for ozekibart to treat conventional chondrosarcoma. This approval sets a PDUFA decision date for April 14, 2027, converting a development-stage asset into ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inbx/inhibrx-biosciences/news/the-bull-case-for-inhibrx-biosciences-inbx-could-change-foll", "source_name": "Simply Wall Street", "published_at": "2026-06-23T20:10:22", "published_display": "23 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(INBX) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) using AI models to provide institutional trading strategies. Key findings indicate a positive near-term sentiment but a weak mid-term bias within a long-term strong context, with an exceptional 97.9:1 risk-reward setup.", "url": "https://news.stocktradersdaily.com/news_release/10/INBX_as_a_Liquidity_Pulse_for_Institutional_Tactics_062026023802_1781980682.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T14:40:40", "published_display": "20 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart", "summary": "Inhibrx Biosciences (INBX) is gaining attention after the FDA accepted its Biologics License Application for ozekibart, used in treating chondrosarcoma, supported by positive trial data. While the stock has seen a significant one-year return, its 30-day performance shows a recent", "url": "https://www.sahmcapital.com/news/content/inhibrx-biosciences-inbx-stock-near-analyst-target-after-fda-filing-for-ozekibart-2026-06-20", "source_name": "Sahm", "published_at": "2026-06-19T23:09:44", "published_display": "19 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history", "summary": "Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company specializing in novel biologic therapeutics for life-threatening conditions, particularly oncology and rare diseases, using its proprietary single-domain antibody (sdAb) platform. Following a spin-off ", "url": "https://www.bitget.com/stock/nasdaq-inbx/what-is", "source_name": "Bitget", "published_at": "2026-06-19T20:40:40", "published_display": "19 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Inhibrx Biosciences Inc (INBX)'s dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both historical dividend dates and stock splits. The piece highl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inbx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:09", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com", "summary": "Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 2.6% after the FDA accepted its drug application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma. The FDA set an April 14, 2027 goal date, with ozekibart poised to be the first FDA-approved t", "url": "https://za.investing.com/news/stock-market-news/inhibrx-biosciences-stock-gains-after-fda-accepts-drug-filing-93CH-4328649", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T07:40:46", "published_display": "16 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA\u2019s Ozekibart BLA Acceptance for Chondrosarcoma Could Shape Inhibrx Biosciences (INBX) Investors", "summary": "The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart to treat chondrosarcoma, setting a PDUFA date of April 14, 2027. This acceptance strengthens the regulatory timeline but highlights the company's single-asset concentration and ongoing losses. I", "url": "https://www.sahmcapital.com/news/content/how-fdas-ozekibart-bla-acceptance-for-chondrosarcoma-could-shape-inhibrx-biosciences-inbx-investors-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-15T20:40:40", "published_display": "15 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy", "summary": "The FDA has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027. This marks a significant milestone as ozekibart could become the f", "url": "https://www.stocktitan.net/sec-filings/INBX/8-k-inhibrx-biosciences-inc-reports-material-event-85a009ffdc56.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:08:58", "published_display": "15 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com", "summary": "The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma, setting an April 14, 2027, goal date. Ozekibart, if approved, would be the first FDA-approved treatment for this rare bon", "url": "https://m.au.investing.com/news/stock-market-news/fda-accepts-inhibrx-filing-for-rare-bone-cancer-treatment-93CH-4487494?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-15T18:08:58", "published_display": "15 Jun 2026 18:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma", "summary": "Inhibrx Biosciences, Inc. announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma. The FDA set a PDUFA goal date of April 14, 2027, with no identified ", "url": "https://www.prnewswire.com/news-releases/inhibrx-announces-us-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conventional-chondrosarcoma-302800101.html", "source_name": "PR Newswire", "published_at": "2026-06-15T13:39:52", "published_display": "15 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22", "summary": "Inhibrx Biosciences director Douglas Forsyth was granted stock options for 15,000 shares of common stock at an exercise price of $95.22 per share. These options, which are a form of equity compensation, will become fully exercisable on June 3, 2027, provided Forsyth continues his", "url": "https://www.stocktitan.net/sec-filings/INBX/form-4-inhibrx-biosciences-inc-insider-trading-activity-8b823f224558.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:39:05", "published_display": "04 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOckpRLVpHNUJfNmFBMmNCU2d3MzNna2FjU2hVRV9YenpYdzg3MU9DREpRcENaVHF5eXJGR3NPbkprMTBjektHRHlzekhRTldod0xGMlREOUJxNUdWWThkRTVRN0RLQ2NVTFo5dkMzWHMyblp5SnlpVEV6aEcwZDhtbDIzT2xoT0tZUE9PTGlZZjRBQ0hJX1NvRi1fNVlEdTVaTF9pd21JOER2cWJ4eDBqMGFB?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQY3A0LVhXaWtvdHQ1d2g4NFlVMFRRNzlaMGhCQ2ZwZWtMMEV3MUJMR1J1SXU5aWFyS3pKZjdlNGJvN3dwTUVWOUJYRzNhVExQU2Fpd1REMUdSc0Fwb3BEenh0YXFNemdNazVwSFlxRElxSmxWRDc4MmlJcDMzcXhjLUxjM1JPSHBnaG5XbkcxQml5OGJPSjFpbUFzRFJBd2x5Y2FqbEpneU1TQVpq?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx seeks FDA OK for cancer drug as Q1 loss totals $33.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNmhoNnhGN09aV25QRTdwUkZtVXV6dkE1T09TWjdLRlZheG96NjFsUjZlZkozWmwzRU5iUjRUWkowU3pJMW16aDlGcGZvQVAzQjA2YXlHdGpXLUlTeXlOcjhjWHZaY1QxRFA3bGZ0VkFCaEx5OXd4Skcxa28xZmthZ3hUSXZGZmxoaTZBUHhQREZfZXB0Q0QtWEh0QW5TMkNU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNcTMtTnE5bHZmMXYtVTdidERyZmoyc21qdGdsWXpGX2hLc0IwbmRDQjlpMUFHbWRJdV96TGx4eGhnX29EYjR2eUVWckZTc3lJNDRnbzF3OFRrdGxlT0NYOGJKMmlTby1lcGtFS2JCN29UUXMwa1RmRk0xd2RHMW4yNkRkUW1fQlF3MWJOenlOX2VNcjI1T19aMUlaMA?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences\u2019 INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study", "summary": "", "url": "https://finance.yahoo.com/m/37eca57e-b180-33fc-95f5-fd74694f8f62/inhibrx-biosciences%E2%80%99.html", "source_name": "MarketBeat", "published_at": "2026-05-11T16:08:17+00:00", "published_display": "11 May 2026 16:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Says INBRX-106 With Pembrolizumab Achieves Higher Response Rate in Phase 2 Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inhibrx-says-inbrx-106-pembrolizumab-143602201.html", "source_name": "MT Newswires", "published_at": "2026-05-11T14:36:02+00:00", "published_display": "11 May 2026 14:36", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer trial: Inhibrx combo lifts head and neck response rate to 44%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTm55bTMzclpnd0hUR1lWQXhCMTAxUDN1WG5zc3laRXNYNjBiaWgxbnVFZk8zYU84UEdZSlpHdklKWTlFX3ZSclpKeGZPQUR1TUY4eVV4cUR6MEN3MG9vSkU5aVY2VnZ3OTBjS0l2WXlweTkyQ1FJTUxneWJoc0ljQ1gycms5aVI0SFd0X2x5WlBvd1habTYxVlhCbFprd05sTThRVkVEekpoWi1IcG1Uc0JMRkFxMU9YLTRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today: $91.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9EcUlOQzNJcHlpTVpCT0pKR1diZHJqaDE4RE95Rmd4LTBfa2RNQjlHSHBWckx3YWplb1RHcHRNYW1fNXQ3cThBMENCTFRjdnVWRWMxQXhORQ?oc=5", "source_name": "Gotrade", "published_at": "2026-05-05T18:04:51+00:00", "published_display": "05 May 2026 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUVhROS12VF9EOVlXbDJ0b09MYXZwRWpVMXBJNlFZOVFCb3pLMjQwUi1kSHhPbGNlVmJnUUFzbDJVek84YWxyOG93WE50VmIzWXNCT0lyUUNNMXpnbUF1WWxodUUtQm1NeWw2X0Vzbmh0eG5zSzdDSlhNTlNWanczWEVjMnR3WE94LWZIN2I0RmRaVGZfVHNGY2N5WjY1eEQ4SUFBM2hycWc5NHpLUFFxRmRNcw?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQWHRObXNxVXdRcS1HejNFQmVQTVF6VjJIQlplZEhIUVhwRjFmT0NwNzJ5ZlM3NzN4MnJldzZ6V05saURHSWhwMDFQVWRWSkR1V01FTmV1c3d4eUhIcGN5U0QxaGtKWkJwLTdFQXJUSGRCQ21IalRqdjN6Vmp1ZDVROE5tYmhXalhDVE5FVm9Hc3ZOWmhmdTRIZmpPZTBwU0VHa0E?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should I buy Inhibrx Biosciences, Inc. (INBX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE92YkJiZlBYZmgzbWtxVFpQU1M2M1BqZzBBeVM1N2VreGU2N1d1cXUtSjZqcnF6ODZLS0Zrd2tXM25udXQycnNGZmk3eWNkSnJzSHlqOXlXZUJWbFVtZkVTN0swTGdPazcySXkzNw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue (NASDAQ:INBX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeW9yTmFhWWtaeEpZaDRxUUZBc1ZIZTdXeGJYcENmbUdWT0QxWEdGRUJlVGc1a29rMFZZcERpTUJsdUhfdEphRGZ3Q0FEUkpOVkthbkxvblhhQlNzX2xjZS10cWxZamZiX2ZzWkNlazhOWE5XTzFlNU5NRHI1Q3NrMGRORjBDY0xER0VLUVNpOTd6bkNqZ0lCN3dSNFJrZFI2amFUOElFV3F5ZHRaZ3ljZjdIUmk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "87% disease control lifts Inhibrx drug in late-line colorectal cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQby1SUDZVSWoyaEpDa1ZnT2g2aE55U2Nfd3g1R19SZWxqWHJLcDR2VWxQcE1LeWUtNURlZlVYWkg1ZDBXSEMtSUg1RUZaYi05Qm4xSzNDZEw3eVl1VGtObTJoT1VMWTRNcUJseVAxYkQ4U0FBSFdPQlNOdngzZG14endpeTQ3UmZ0QXF6Q3QxekFvcDVXQU1TcEN5b3lOOFV4R2gxTWVFQVo4Zms1Nm1YcEZpUHNvT04yMHFjaVlFckE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inhibrx Biosciences (INBX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9rQ29BT0oxeGVkdUozbzVUaUJEYWZHQTVFbWljYnBwR2dEd19NQjZyNWkyaW1jc1FFdHhTQkpmZTlWREFfdHByZW01NmVGUklrOHduNWN6SmtiZw?oc=5", "source_name": "MarketBeat", "published_at": "2020-08-26T06:08:33+00:00", "published_display": "26 Aug 2020 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INBX Stock Price and Chart \u2014 NASDAQ:INBX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5pZnFnSWlPWkdvck1tLXRqRV9wY0JRNkdoWW9zSUJzUTdwcmdPNTZtYVhDaExzVzlneFpDQy04emtrekpENkJWTnVsdXFwRERwYW9BaFFWR1FXUjFJ?oc=5", "source_name": "TradingView", "published_at": "2020-08-20T07:00:00+00:00", "published_display": "20 Aug 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQOWpidFh1WDNOcnJPWXlhX1Q0LTUyWVowa2hELXhBc0c4NEFMVFpwVGZ4c0dHaUxBUTB6bi1YN0p2dXhVcjBJaUJMOC0zTzh5X3EtRngwX0pWRXpXNHB1M2FLUEdLaE5WekxYTEFsVzc1ZmtHOURzZ3Fnenk1YTdieE9nSk9sX0d6WGJORmtnMnFsVVpoT1VscXB5LWkyNVVQRGUtMkRfbWhKQXd2?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-17T10:43:05+00:00", "published_display": "17 Jul 2026 10:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million", "summary": "Inhibrx Biosciences has expanded its loan facility with Oxford Finance to $500 million through a second amendment to their agreement. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately as a Term C Loan and an additional $225 million ", "url": "https://www.bitget.com/amp/news/detail/12560605510756", "source_name": "Bitget", "published_at": "2026-07-17T08:39:58", "published_display": "17 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants", "summary": "Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collat", "url": "https://www.tradingview.com/news/tradingview:aa55e8e1012b4:0-inhibrx-biosciences-expands-oxford-credit-facility-to-500-million-draws-100-million-issues-warrants/", "source_name": "TradingView", "published_at": "2026-07-16T20:11:03", "published_display": "16 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit", "summary": "Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an 8", "url": "https://www.stocktitan.net/sec-filings/INBX/8-k-inhibrx-biosciences-inc-reports-material-event-d6a556c7ff36.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:11:03", "published_display": "16 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million", "summary": "Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its dr", "url": "https://www.moomoo.com/th/news/post/73079525/press-release-inhibrx-announces-amended-loan-agreement-with-oxford-finance", "source_name": "Moomoo", "published_at": "2026-07-16T19:10:59", "published_display": "16 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/inhibrx-announces-amended-loan-agreement-130000546.html", "source_name": "PR Newswire", "published_at": "2026-07-16T13:00:00+00:00", "published_display": "16 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Gets $100 Million Now; Lenders May Fund $225 Million More", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOYjQ3Y2VWakZIbDVyU25jVzBnc2wyX3l0N2t6cmdZNkQyOE9Qby1nQ3oxZUxnSXE2VTFDNWQwRGVIWmxXYWFTMF9IUHBDaVpNdEJlVEgtS0Q3dzNRU2hnSzhfZVVTT3RBaHN4NHRZUTRab1d3eklIeWtCMDB2bnctWHlwMEZqOXlGZ2dldjEtM2F0WXVQWUM4eGFNR3piUTlsOEplQ0V3V3VLUGJ0elB5OXYtTklIUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T13:00:00+00:00", "published_display": "16 Jul 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (INBX) for Rule-Based Strategy", "summary": "Inhibrx Biosciences Inc (NASDAQ: INBX) is showing strong sentiment across all horizons, supporting an overweight bias. AI models have generated three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles. The analysi", "url": "https://news.stocktradersdaily.com/news_release/1/Price-Driven_Insight_from_INBX_for_Rule-Based_Strategy_071226045802_1783889882.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T16:58:00", "published_display": "12 Jul 2026 16:58", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Inhibrx Biosciences' (INBX) Shift Into Russell Growth Indexes Reframe Its Core Investment Story?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPSzY4SmFpbDViUk9tTXQ2NS15X1pYZUhqNVZlY2tWak5udkdGcGxRVW5XYjdSVWg5dDM1UlJkVUlXNXd3ZDdiaXBILUlvQWR3Wnl2UmNScHVVczZfbUJ4TzRWOGJHYUl6VjYwZEFEQzJxQS1NRFN1SExjcTEwNDR5Y1k4MGZXeFlIdFpCcGc0YlEwQV9EUC1hWnNR?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights", "summary": "This report provides a stock analysis for Inhibrx Biosciences (INBX), a clinical-stage biopharmaceutical company. It details the company's general information, current stock performance, and a methodology for grading the stock based on various financial metrics. The analysis high", "url": "https://es.benzinga.com/quote/INBX/report", "source_name": "Benzinga Espa\u00f1a", "published_at": "2026-07-07T06:11:48", "published_display": "07 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors", "summary": "Inhibrx Biosciences (INBX) was reclassified from Russell value/defensive indices to growth/small-cap indices in late June 2026. This shift primarily affects the type of investors holding the stock and doesn't change the underlying business catalysts, which include regulatory prog", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inbx/inhibrx-biosciences/news/how-russell-index-reclassification-toward-growth-benchmarks", "source_name": "Simply Wall Street", "published_at": "2026-07-03T02:40:11", "published_display": "03 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(INBX) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) price dynamics, identifying a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 97.2:1 risk-reward setup, targeting a substantial gain with minimal risk. The analysis provides t", "url": "https://news.stocktradersdaily.com/news_release/9/INBX_Price_Dynamics_and_Execution-Aware_Positioning_070126035001_1782935401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T15:40:44", "published_display": "01 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index", "summary": "Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been removed from the Russell 2000 Defensive Index. This change is part of broader index adjustments, as the company was also added to other Russell indices like the Russell 2500 Growth and Russell 2000 Growth Benchmarks around the s", "url": "https://www.marketscreener.com/news/inhibrx-biosciences-inc-nasdaqgs-inbx-dropped-from-russell-2000-defensive-index-ce7f5fdfdc8af427", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:12:39", "published_display": "29 Jun 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?", "summary": "Inhibrx Biosciences (INBX) received FDA acceptance for its Biologics License Application for ozekibart, following positive Phase III data. Despite significant past share price momentum and an analyst target considerably higher than the current trading price, the company's financi", "url": "https://www.sahmcapital.com/news/content/inhibrx-biosciences-inbx-wins-fda-filing-acceptance-is-more-upside-already-priced-in-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-29T13:12:39", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark", "summary": "Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been added to the Russell 3000E Growth Benchmark. This pharmaceutical company, which specializes in developing novel biologic therapeutic candidates, is actively advancing its clinical pipeline, including therapies like ozekibart (IN", "url": "https://www.marketscreener.com/news/inhibrx-biosciences-inc-nasdaqgs-inbx-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:41:49", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index", "summary": "Inhibrx Biosciences, Inc. (NasdaqGS:INBX) has been removed from the Russell 2000 Value-Defensive Index. This change is part of broader Russell index reconfigurations, which also saw the company dropped from other defensive/value benchmarks and added to growth benchmarks like the ", "url": "https://www.marketscreener.com/news/inhibrx-biosciences-inc-nasdaqgs-inbx-dropped-from-russell-2000-value-defensive-index-ce7f5fdfde80f325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:09:48", "published_display": "29 Jun 2026 03:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Inhibrx Biosciences, Inc. \u2013 NASDAQ:INBX", "summary": "This article provides a financial snippet for Inhibrx Biosciences, Inc. (NASDAQ: INBX), focusing on its enterprise value to revenue forward metric. It details that the market is currently closed with no trades recorded for the company. The content appears to be a stub or a brief ", "url": "https://www.tradingview.com/symbols/NASDAQ-INBX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:12", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Inhibrx Biosciences, Inc. \u2013 NASDAQ:INBX", "summary": "This article provides financial data, specifically the \"Price to sales forward\" for Inhibrx Biosciences, Inc. (NASDAQ: INBX). It notes that the market is closed with no trades recorded at the time of publication and lists the company on the Nasdaq Stock Market. The content is pri", "url": "https://www.tradingview.com/symbols/NASDAQ-INBX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:34", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Jun 2026", "summary": "Inhibrx Biosciences (INBX) reported a short interest of 3.30 million shares as of June 15, 2026, representing 27.52% of its public float, an increase of 3.79% from the previous report. The short interest ratio is 10.3 days to cover, indicating significant pessimism towards the st", "url": "https://www.marketbeat.com/stocks/NASDAQ/INBX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T00:10:12", "published_display": "26 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INBX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Inhibrx Biosciences, Inc. (INBX) stock, including analyst price targets, past performance, and basic financial information. It notes that analysts have a maximum estimate of $325.00 and a minimum estimate of $230.00 for INBX's future price. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-INBX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:10:07", "published_display": "25 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More", "summary": "This article highlights six biotech stocks (Inhibrx Biosciences, Palvella Therapeutics, MBX Biosciences, Protagonist Therapeutics, Absci Corp., and Belite Bio Inc) that have shown significant gains for long-term investors. It details the clinical developments, positive trial resu", "url": "https://www.rttnews.com/amp/3662423/6-biotech-stocks-that-delivered-stunning-gains-inbx-700-pvla-500-mbx-300-absi-200-more.aspx", "source_name": "RTTNews", "published_at": "2026-06-24T13:39:50", "published_display": "24 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart", "summary": "Inhibrx Biosciences' investment narrative is shifting due to the FDA's acceptance of its Biologics License Application (BLA) for ozekibart to treat conventional chondrosarcoma. This approval sets a PDUFA decision date for April 14, 2027, converting a development-stage asset into ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inbx/inhibrx-biosciences/news/the-bull-case-for-inhibrx-biosciences-inbx-could-change-foll", "source_name": "Simply Wall Street", "published_at": "2026-06-23T20:10:22", "published_display": "23 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(INBX) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) using AI models to provide institutional trading strategies. Key findings indicate a positive near-term sentiment but a weak mid-term bias within a long-term strong context, with an exceptional 97.9:1 risk-reward setup.", "url": "https://news.stocktradersdaily.com/news_release/10/INBX_as_a_Liquidity_Pulse_for_Institutional_Tactics_062026023802_1781980682.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T14:40:40", "published_display": "20 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart", "summary": "Inhibrx Biosciences (INBX) is gaining attention after the FDA accepted its Biologics License Application for ozekibart, used in treating chondrosarcoma, supported by positive trial data. While the stock has seen a significant one-year return, its 30-day performance shows a recent", "url": "https://www.sahmcapital.com/news/content/inhibrx-biosciences-inbx-stock-near-analyst-target-after-fda-filing-for-ozekibart-2026-06-20", "source_name": "Sahm", "published_at": "2026-06-19T23:09:44", "published_display": "19 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history", "summary": "Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company specializing in novel biologic therapeutics for life-threatening conditions, particularly oncology and rare diseases, using its proprietary single-domain antibody (sdAb) platform. Following a spin-off ", "url": "https://www.bitget.com/stock/nasdaq-inbx/what-is", "source_name": "Bitget", "published_at": "2026-06-19T20:40:40", "published_display": "19 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Inhibrx Biosciences Inc (INBX)'s dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both historical dividend dates and stock splits. The piece highl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inbx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:09", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com", "summary": "Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 2.6% after the FDA accepted its drug application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma. The FDA set an April 14, 2027 goal date, with ozekibart poised to be the first FDA-approved t", "url": "https://za.investing.com/news/stock-market-news/inhibrx-biosciences-stock-gains-after-fda-accepts-drug-filing-93CH-4328649", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T07:40:46", "published_display": "16 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How FDA\u2019s Ozekibart BLA Acceptance for Chondrosarcoma Could Shape Inhibrx Biosciences (INBX) Investors", "summary": "The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart to treat chondrosarcoma, setting a PDUFA date of April 14, 2027. This acceptance strengthens the regulatory timeline but highlights the company's single-asset concentration and ongoing losses. I", "url": "https://www.sahmcapital.com/news/content/how-fdas-ozekibart-bla-acceptance-for-chondrosarcoma-could-shape-inhibrx-biosciences-inbx-investors-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-15T20:40:40", "published_display": "15 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy", "summary": "The FDA has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027. This marks a significant milestone as ozekibart could become the f", "url": "https://www.stocktitan.net/sec-filings/INBX/8-k-inhibrx-biosciences-inc-reports-material-event-85a009ffdc56.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:08:58", "published_display": "15 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com", "summary": "The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma, setting an April 14, 2027, goal date. Ozekibart, if approved, would be the first FDA-approved treatment for this rare bon", "url": "https://m.au.investing.com/news/stock-market-news/fda-accepts-inhibrx-filing-for-rare-bone-cancer-treatment-93CH-4487494?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-15T18:08:58", "published_display": "15 Jun 2026 18:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma", "summary": "Inhibrx Biosciences, Inc. announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma. The FDA set a PDUFA goal date of April 14, 2027, with no identified ", "url": "https://www.prnewswire.com/news-releases/inhibrx-announces-us-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conventional-chondrosarcoma-302800101.html", "source_name": "PR Newswire", "published_at": "2026-06-15T13:39:52", "published_display": "15 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22", "summary": "Inhibrx Biosciences director Douglas Forsyth was granted stock options for 15,000 shares of common stock at an exercise price of $95.22 per share. These options, which are a form of equity compensation, will become fully exercisable on June 3, 2027, provided Forsyth continues his", "url": "https://www.stocktitan.net/sec-filings/INBX/form-4-inhibrx-biosciences-inc-insider-trading-activity-8b823f224558.html", "source_name": "Stock Titan", "published_at": "2026-06-04T21:39:05", "published_display": "04 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOckpRLVpHNUJfNmFBMmNCU2d3MzNna2FjU2hVRV9YenpYdzg3MU9DREpRcENaVHF5eXJGR3NPbkprMTBjektHRHlzekhRTldod0xGMlREOUJxNUdWWThkRTVRN0RLQ2NVTFo5dkMzWHMyblp5SnlpVEV6aEcwZDhtbDIzT2xoT0tZUE9PTGlZZjRBQ0hJX1NvRi1fNVlEdTVaTF9pd21JOER2cWJ4eDBqMGFB?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQY3A0LVhXaWtvdHQ1d2g4NFlVMFRRNzlaMGhCQ2ZwZWtMMEV3MUJMR1J1SXU5aWFyS3pKZjdlNGJvN3dwTUVWOUJYRzNhVExQU2Fpd1REMUdSc0Fwb3BEenh0YXFNemdNazVwSFlxRElxSmxWRDc4MmlJcDMzcXhjLUxjM1JPSHBnaG5XbkcxQml5OGJPSjFpbUFzRFJBd2x5Y2FqbEpneU1TQVpq?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx seeks FDA OK for cancer drug as Q1 loss totals $33.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNmhoNnhGN09aV25QRTdwUkZtVXV6dkE1T09TWjdLRlZheG96NjFsUjZlZkozWmwzRU5iUjRUWkowU3pJMW16aDlGcGZvQVAzQjA2YXlHdGpXLUlTeXlOcjhjWHZaY1QxRFA3bGZ0VkFCaEx5OXd4Skcxa28xZmthZ3hUSXZGZmxoaTZBUHhQREZfZXB0Q0QtWEh0QW5TMkNU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNcTMtTnE5bHZmMXYtVTdidERyZmoyc21qdGdsWXpGX2hLc0IwbmRDQjlpMUFHbWRJdV96TGx4eGhnX29EYjR2eUVWckZTc3lJNDRnbzF3OFRrdGxlT0NYOGJKMmlTby1lcGtFS2JCN29UUXMwa1RmRk0xd2RHMW4yNkRkUW1fQlF3MWJOenlOX2VNcjI1T19aMUlaMA?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences\u2019 INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study", "summary": "", "url": "https://finance.yahoo.com/m/37eca57e-b180-33fc-95f5-fd74694f8f62/inhibrx-biosciences%E2%80%99.html", "source_name": "MarketBeat", "published_at": "2026-05-11T16:08:17+00:00", "published_display": "11 May 2026 16:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Says INBRX-106 With Pembrolizumab Achieves Higher Response Rate in Phase 2 Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inhibrx-says-inbrx-106-pembrolizumab-143602201.html", "source_name": "MT Newswires", "published_at": "2026-05-11T14:36:02+00:00", "published_display": "11 May 2026 14:36", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer trial: Inhibrx combo lifts head and neck response rate to 44%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTm55bTMzclpnd0hUR1lWQXhCMTAxUDN1WG5zc3laRXNYNjBiaWgxbnVFZk8zYU84UEdZSlpHdklKWTlFX3ZSclpKeGZPQUR1TUY4eVV4cUR6MEN3MG9vSkU5aVY2VnZ3OTBjS0l2WXlweTkyQ1FJTUxneWJoc0ljQ1gycms5aVI0SFd0X2x5WlBvd1habTYxVlhCbFprd05sTThRVkVEekpoWi1IcG1Uc0JMRkFxMU9YLTRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today: $91.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9EcUlOQzNJcHlpTVpCT0pKR1diZHJqaDE4RE95Rmd4LTBfa2RNQjlHSHBWckx3YWplb1RHcHRNYW1fNXQ3cThBMENCTFRjdnVWRWMxQXhORQ?oc=5", "source_name": "Gotrade", "published_at": "2026-05-05T18:04:51+00:00", "published_display": "05 May 2026 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUVhROS12VF9EOVlXbDJ0b09MYXZwRWpVMXBJNlFZOVFCb3pLMjQwUi1kSHhPbGNlVmJnUUFzbDJVek84YWxyOG93WE50VmIzWXNCT0lyUUNNMXpnbUF1WWxodUUtQm1NeWw2X0Vzbmh0eG5zSzdDSlhNTlNWanczWEVjMnR3WE94LWZIN2I0RmRaVGZfVHNGY2N5WjY1eEQ4SUFBM2hycWc5NHpLUFFxRmRNcw?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQWHRObXNxVXdRcS1HejNFQmVQTVF6VjJIQlplZEhIUVhwRjFmT0NwNzJ5ZlM3NzN4MnJldzZ6V05saURHSWhwMDFQVWRWSkR1V01FTmV1c3d4eUhIcGN5U0QxaGtKWkJwLTdFQXJUSGRCQ21IalRqdjN6Vmp1ZDVROE5tYmhXalhDVE5FVm9Hc3ZOWmhmdTRIZmpPZTBwU0VHa0E?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Inhibrx Biosciences, Inc. (INBX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE92YkJiZlBYZmgzbWtxVFpQU1M2M1BqZzBBeVM1N2VreGU2N1d1cXUtSjZqcnF6ODZLS0Zrd2tXM25udXQycnNGZmk3eWNkSnJzSHlqOXlXZUJWbFVtZkVTN0swTGdPazcySXkzNw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue (NASDAQ:INBX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeW9yTmFhWWtaeEpZaDRxUUZBc1ZIZTdXeGJYcENmbUdWT0QxWEdGRUJlVGc1a29rMFZZcERpTUJsdUhfdEphRGZ3Q0FEUkpOVkthbkxvblhhQlNzX2xjZS10cWxZamZiX2ZzWkNlazhOWE5XTzFlNU5NRHI1Q3NrMGRORjBDY0xER0VLUVNpOTd6bkNqZ0lCN3dSNFJrZFI2amFUOElFV3F5ZHRaZ3ljZjdIUmk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "87% disease control lifts Inhibrx drug in late-line colorectal cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQby1SUDZVSWoyaEpDa1ZnT2g2aE55U2Nfd3g1R19SZWxqWHJLcDR2VWxQcE1LeWUtNURlZlVYWkg1ZDBXSEMtSUg1RUZaYi05Qm4xSzNDZEw3eVl1VGtObTJoT1VMWTRNcUJseVAxYkQ4U0FBSFdPQlNOdngzZG14endpeTQ3UmZ0QXF6Q3QxekFvcDVXQU1TcEN5b3lOOFV4R2gxTWVFQVo4Zms1Nm1YcEZpUHNvT04yMHFjaVlFckE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibrx Biosciences (INBX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9rQ29BT0oxeGVkdUozbzVUaUJEYWZHQTVFbWljYnBwR2dEd19NQjZyNWkyaW1jc1FFdHhTQkpmZTlWREFfdHByZW01NmVGUklrOHduNWN6SmtiZw?oc=5", "source_name": "MarketBeat", "published_at": "2020-08-26T06:08:33+00:00", "published_display": "26 Aug 2020 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INBX Stock Price and Chart \u2014 NASDAQ:INBX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5pZnFnSWlPWkdvck1tLXRqRV9wY0JRNkdoWW9zSUJzUTdwcmdPNTZtYVhDaExzVzlneFpDQy04emtrekpENkJWTnVsdXFwRERwYW9BaFFWR1FXUjFJ?oc=5", "source_name": "TradingView", "published_at": "2020-08-20T07:00:00+00:00", "published_display": "20 Aug 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 57, "sentiment_summary": {"positive": 23, "negative": 4, "neutral": 30, "score": 58, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 19.2, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 87.39, "latest_week": "2026-07-17", "one_week_move": -6.0, "four_week_move": -6.1, "twelve_week_move": -32.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.343876, "market_dynamics_buy_signal": false, "relative_strength": 13.341881, "fair_value_gap": 115.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.9197, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.0% over one week, -6.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "PR Newswire", "count": 3}, {"label": "Stock Traders Daily", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Sahm", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 12}, {"label": "Balance sheet", "count": 4}, {"label": "Regulatory and legal", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.0% over one week, -6.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX)"}], "updated_at": "2026-07-22T23:51:38.526987+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}